Day: February 18, 2025

Hamilton, Bermuda February 18, 2025 Øystein Kalleklev, CEO of Avance Gas AS and Board member of Avance Gas Holding Ltd, has on February 17, exercised his remaining 150,000 share options at terms described in attachments. The stock options have been cash settled with the difference of the Adjusted Strike Price and the closing price at OSE on February 17, 2025.  Following the exercise, Mr Kalleklev has no further share options in Avance Gas Holding Ltd. but holds 50,000 shares. Please see the attached form for notification and public disclosure of transaction. For further information, please contact: Investor and Analyst Contact: Randi Navdal Bekkelund, Chief Financial Officer of Avance Gas Tel: +47 23 11 40 00 Media Contact: Øystein Kalleklev, Chief Executive Officer of Avance Gas Tel: +47 23 11 40 00 This information is subject to the...

Reference is made to the announcement by IDEX Biometrics ASA (“IDEX”) on 28 January 2025 regarding the arbitration decision on 27 January 2025 on the dispute between IDEX and Zwipe AS (“Zwipe”), whereby the arbitrator held in favor of IDEX on all counts. The due date for payments by Zwipe was 14 days from the date of the arbitration decision. Following such due date, because of Zwipe’s financial situation, as communicated by Zwipe on Euronext Oslo Børs, IDEX has engaged in discussions with Zwipe about a payment plan for the arbitration award. However, such discussions effectively ended when Zwipe on 17 February 2025 announced that it will file for bankruptcy with the Oslo District Court. While Zwipe has paid the arbitration costs, Zwipe has made no payment to IDEX in compliance with the arbitration award. This information...

Total revenue increased by 32% to CHF 209m Operating profit tripled to CHF 61m Operating cash flow significantly increased to CHF 74mAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 18, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today its results for the financial year ended December 31, 2024. David Veitch, Chief Executive Officer, stated: “2024 was a very successful year. We have achieved major milestones, including the approval of Zevtera in the United States and the subsequent partnering with Innoviva Specialty Therapeutics, IST, for the commercialization of Zevtera in the US. While Cresemba remains our most successful commercial brand, we expect increasing...